Faruqi and Faruqui, LLP Logo
Share this page

Northwest Biotherapeutics, Inc. (NWBO)

(NASDAQ: NWBO)

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Northwest Biotherapeutics, Inc. (NWBO) To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Northwest Biotherapeutics, Inc. (“Northwest” or the “Company”) (NASDAQ: NWBO).

On June 19, 2014, TheStreet.com published an article stating that “[t]he prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct… MD Anderson is running the DCVax-Direct phase I/II clinical trial with funding from Northwest Bio[therapeutics], which makes the hospital’s criticism of the company’s tactics even more significant.”

Following this news, the price of Northwest shares declined by $1.79 per share, or over 19%, to close on June 19, 2014 at $7.18 per share.

Take Action

If you invested in Northwest stock or options prior to June 19, 2014 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Northwest’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 07/03/2014

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.